

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

The current listing of claims replaces any and all previous listing of claims.

1-5 (Cancelled)

6-15 (Cancelled)

16. (Cancelled)

17. (Currently amended) The compound or salt of claim ~~5~~ 44, wherein R¹ is selected from the group consisting of alkyl, cycloalkyl, alkenyl, and alkynyl.

18. (Original) The compound or salt of claim 17, wherein R³ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and aryl.

19. (Original) The compound or salt of claim 18, wherein R⁴ is hydrogen.

20. (Cancelled)

21. (Currently amended) The compound or salt of claim ~~20~~ 19, wherein Z is oxygen.

22. (Currently amended) The compound or salt of claim 21, wherein R⁵, ~~R⁶~~, R⁸, and R⁹ are hydrogen.

23. (Original) The compound or salt of claim 22, wherein R⁷ is selected from the group consisting of trihalomethyl and trihalomethanesulfonyl.

24. (Cancelled)

25. (Currently amended) The compound or salt of claim ~~24~~ 22, wherein R⁶ and R⁷ are taken together with the atoms to which they are attached ~~combine~~ to form a methylenedioxy or a 1,3-dioxano group.

26-29. (Cancelled)

30. (Currently amended) A method for the treatment ~~or prevention~~ of a disorder characterized by inappropriate protein kinase activity comprising administering to an organism afflicted with such a disorder a therapeutically effective amount of one or more of said compounds of claim ~~4~~ 44 or a physiologically acceptable salt thereof.

31. (Currently amended) The method of claim 30 wherein said therapeutically effective amount of said compound of claim ~~4~~ 44 ~~comprises~~ is administered as a pharmacological composition.

32. (Currently amended) A pharmacological composition of said compound of claim ~~4~~ 44.

33. (Currently amended) The method of claim 30 wherein said organism ~~comprises~~ is a mammal.

34. (Original) The method of claim 33 wherein said mammal is a human.

35. (Cancelled)

36. (Currently amended) The method of claim 35 ~~30~~ wherein said disorder is a cancer is selected from the group consisting of brain cancer, colon cancer, prostate cancer, kidney cancer, breast cancer, lung cancer, salivary gland cancer, oral cancer, pancreatic cancer, bladder cancer, Kaposi's sarcoma, melanoma, and ovarian cancer.

37. (Original) The method of claim 30 wherein said disorder comprises a skeletal disorder.

38. (Original) The method of claim 30 wherein said disorder comprises a fibrotic disorder.

39. (Original) The method of claim 30 wherein said disorder comprises a blood vessel proliferative disorder.


40. (Currently amended) The method of claim 38 wherein said fibrotic disorder comprises restinosis, hepatic cirrhosis, glomerular sclerosis, interstitial nephritis, interstitial pulmonary fibrosis, atherosclerosis, wound scarring ~~and~~ or scleroderma.

41. (Currently amended) A method of inhibiting the metastasis of a cancer comprising administering to an organism in need of such inhibition a therapeutically effective amount of one or more compounds of claim 4 ~~44~~.

42. (Currently amended) The method of claim 41 wherein said therapeutically effective amount of one or more compounds of claim 4 44 is administered as ~~comprises~~ a pharmacological composition.

43. (Currently amended) The method of claim 42 ~~41~~ wherein said cancer comprises colon cancer, prostate cancer, pancreatic cancer, Kaposi's sarcoma, ovarian cancer, breast cancer ~~and~~ or gliomas glioma.

44. (New) A compound of the formula:



wherein:

R¹ is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heteroalicyclic;

R³ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heteroalicyclic;

Z is selected from the group consisting of oxygen and sulfur;

R⁴ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, sulfonyl, trihalomethanesulfonyl, hydroxy, alkoxy and C-carboxy;

R⁵, R⁶, R⁸ and R⁹, which may be the same or different, are each independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, cycloalkoxy, aryloxy, heteroaryloxy, heteroalicycloxy, thiohydroxy, thioalkoxy, thiocycloalkoxy, thioheteraryloxy, thioheteralicycloxy, halo, nitro, cyano, C-O-carbamyl, N-carbamyl, silyl, phosphonyl, C-carboxy, O-carboxy, N-amido, C-amido, sulfinyl, sulfonyl, S-sulfoamido, N-sulfoamido, trihalomethanesulfonyl, amino and -NR¹³R¹⁴;

R⁷ is selected from the group consisting of alkyl, trihaloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, cycloalkoxy, aryloxy, heteroaryloxy, heteroalicycloxy, thiohydroxy, thioalkoxy, thiocycloalkoxy, thioheteraryloxy, thioheteralicycloxy, nitro, cyano, C-O-carbamyl, N-carbamyl, silyl, phosphonyl, C-carboxy, O-carboxy, N-amido, C-amido, sulfinyl, sulfonyl, S-sulfoamido, N-sulfoamido, trihalomethanesulfonyl, amino and -NR¹³R¹⁴; or when taken together with the atoms to which they are attached, R⁶ and R⁷ combine to form a methylenedioxy group or a 1,3-dioxano group; and

R¹³ and R¹⁴, which may be the same or different, are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, C-carboxy, sulfonyl, and trihalomethanesulfonyl, or when taken together with the atom to which they are attached, R¹³ and R¹⁴ form a five- or six-membered heteroalicyclic ring containing at least one nitrogen;

and physiologically acceptable salts thereof.